Payment overview · 2025
General Payments
$48.23
2 reported records · 2 companies
Healthcare provider profile · identity verified
Jordan Goodman, MD
Allopathic & Osteopathic Physicians|Family Medicine · BOURBONNAIS, IL · NPI 1538244389
Verified facts
What the public records show
CMS Open Payments records show Jordan Goodman, MD received $48.23 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 55.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.92 | 55.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.31 | 44.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $48.23 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 504 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 478 | 139 |
| Metformin Hcl | Metformin Hcl | 295 | 81 |
| Losartan Potassium | Losartan Potassium | 284 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 70 |
| Lisinopril | Lisinopril | 207 | 65 |
| Tramadol Hcl | Tramadol Hcl | 198 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 60 |
| Gabapentin | Gabapentin | 157 | 43 |
| Alprazolam | Alprazolam | 156 | 34 |
| Simvastatin | Simvastatin | 151 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 26 |
| Clonazepam | Clonazepam | 142 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 40 |
| Omeprazole | Omeprazole | 131 | 48 |
| Furosemide | Furosemide | 119 | 30 |
| Potassium Chloride | Potassium Chloride | 98 | 27 |
| Jardiance | Empagliflozin | 97 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 27 |
| Trazodone Hcl | Trazodone Hcl | 85 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 23 |
| Ozempic | Semaglutide | 75 | suppressed |
| Glipizide | Glipizide | 74 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 23 |
| Sertraline Hcl | Sertraline Hcl | 72 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 14 |
| Allopurinol | Allopurinol | 70 | 20 |
| Carvedilol | Carvedilol | 70 | 28 |
| Glimepiride | Glimepiride | 66 | 20 |
| Meloxicam | Meloxicam | 66 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 24 |
| Montelukast Sodium | Montelukast Sodium | 61 | 22 |
| Lorazepam | Lorazepam | 58 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 13 |
| Eliquis | Apixaban | 45 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 41 | suppressed |
| Famotidine | Famotidine | 40 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Prednisone | Prednisone | 14 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $48.23 · 2 records | AstraZeneca Pharmaceuticals LP | FARXIGA, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error